{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T15:41:01Z","timestamp":1789400461590,"version":"build-2803163510"},"reference-count":50,"publisher":"BMJ","issue":"7","license":[{"start":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T00:00:00Z","timestamp":1753920000000},"content-version":"unspecified","delay-in-days":30,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Grants-in- Aid for Scientific Research (C) from the Ministry of Education, Cultures, Sports, Science and Technology of Japan","award":["22K08088"],"award-info":[{"award-number":["22K08088"]}]},{"name":"Grants-in- Aid for Scientific Research (C) from the Ministry of Education, Cultures, Sports, Science and Technology of Japan","award":["25K11286"],"award-info":[{"award-number":["25K11286"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2025,7,15]]},"published-print":{"date-parts":[[2025,7]]},"abstract":"\n Background<\/jats:title>\n A chemoimmunotherapy regimen consisting of a novel Wilms\u2019 tumor 1 (WT1) peptide-pulsed dendritic cell (WT1-DC) vaccine and multiagent chemotherapy was observed to modulate the tumor microenvironment (TME) to an immunostimulatory state, resulting in conversion surgery in seven out of nine patients with unresectable pancreatic ductal adenocarcinoma (UR-PDAC).<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n Understanding WT1-specific immunity and the tumor mutational burden is important for predicting the efficacy of WT1-targeted chemoimmunotherapy. Therefore, the memory CD8+T\u2009cell subpopulations in WT1-specific cytotoxic T lymphocytes (WT1-CTLs), titers of antibodies against the WT1 epitopes, infiltration of CD103+tissue-resident memory T cells and CD20+cells in the pancreatic TME, gene mutations in plasma circulating tumor DNA (ctDNA) obtained via liquid biopsy, and PDAC cell characteristics were evaluated.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Prior to treatment, patients with a relatively low number of WT1-specific CD8+naive T (Tn) cells, high levels of WT1-specific IgM antibodies, no mutations in any key genes (KRAS<\/jats:italic> and TP53<\/jats:italic>) in plasma ctDNA that were different in each patient (ie, neoantigens), and low levels of programmed death-ligand 1 expression in PDAC cells presented a markedly superior prognosis compared with patients with alternative patterns. Administration of WT1-targeted chemoimmunotherapy resulted in a significant increase in the proportion of circulating WT1-specific CD8+central memory T (Tcm) cells in super-responders (SRs: progression-free survival (PFS)>median) compared with non-super-responders (NSRs: PFS\u2264median). Moreover, the ratio of Tcm to terminally differentiated effector memory T cells in WT1-CTLs was greater in SRs than in NSRs after 15 vaccinations. In patients harboring at least one mutated ctDNA, the frequency of each ctDNA mutant allele significantly decreased after WT1-targeted chemoimmunotherapy. In addition, one SR showed remarkably high infiltration of CD103+ or\u2009CD20+ cells in the pancreatic TME; however, there was no association between these cell densities and clinical outcomes.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n In patients with UR-PDAC who exhibited spontaneous activation of WT1-specific cellular and humoral immunity prior to treatment, endogenous WT1-specific CD8+Tn cells were engineered into WT1-specific memory CD8+cells via WT1-targeted chemoimmunotherapy, resulting in superior therapeutic effects. WT1-targeted chemoimmunotherapy also induced neoantigen-specific immune responses via epitope spreading, leading to the elimination of neoantigen-expressing PDAC cells and favorable clinical outcomes.<\/jats:p>\n <\/jats:sec>\n \n Trial registration number<\/jats:title>\n jRCTc030190195.<\/jats:p>\n <\/jats:sec>","DOI":"10.1136\/jitc-2024-011426","type":"journal-article","created":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T08:45:22Z","timestamp":1753951522000},"page":"e011426","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Predictors of patients with advanced pancreatic cancer undergoing conversion surgery via chemoimmunotherapy with a multifunctional Wilms\u2019 tumor 1 (WT1) peptide cocktail-pulsed dendritic cell vaccine"],"prefix":"10.1136","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0397-4348","authenticated-orcid":false,"given":"Shigeo","family":"Koido","sequence":"first","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Internal Medicine, The Jikei University Kashiwa Hospital, Kashiwa, Chiba, Japan"},{"name":"Department of Cancer Immunotherapy, The University of Osaka Graduate School of Medicine, Suita, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junichi","family":"Taguchi","sequence":"additional","affiliation":[{"name":"Tokyo Midtown Clinic, Minato, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masamori","family":"Shimabuku","sequence":"additional","affiliation":[{"name":"Tokyo Midtown Clinic, Minato, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tuuse","family":"Bito","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Internal Medicine, The Jikei University Kashiwa Hospital, Kashiwa, Chiba, Japan"},{"name":"Institute of Clinical Medicine and Research, The Jikei University School of Medicine, Kashiwa, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4939-0455","authenticated-orcid":false,"given":"Soyoko","family":"Morimoto","sequence":"additional","affiliation":[{"name":"Department of Cancer Stem Cell Biology, The University of Osaka Graduate School of Medicine, Suita, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2935-1184","authenticated-orcid":false,"given":"Yusuke","family":"Oji","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory and Biomedical Sciences, The University of Osaka Graduate School of Medicine, Suita, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-9171-6585","authenticated-orcid":false,"given":"Yoshihiro","family":"Oka","sequence":"additional","affiliation":[{"name":"Department of Cancer Stem Cell Biology, The University of Osaka Graduate School of Medicine, Suita, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Ito","sequence":"additional","affiliation":[{"name":"Institute of Clinical Medicine and Research, The Jikei University School of Medicine, Kashiwa, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoko","family":"Shimizu","sequence":"additional","affiliation":[{"name":"Tokyo Midtown Clinic, Minato, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zensho","family":"Ito","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Internal Medicine, The Jikei University Kashiwa Hospital, Kashiwa, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kan","family":"Uchiyama","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Internal Medicine, The Jikei University Kashiwa Hospital, Kashiwa, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Saruta","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Internal Medicine, The Jikei University School of Medicine, Minato, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhiro","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Microbiota Research, Juntendo University School of Medicine Graduate School of Medicine, Bunkyo, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshifumi","family":"Ohkusa","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Internal Medicine, The Jikei University Kashiwa Hospital, Kashiwa, Chiba, Japan"},{"name":"Department of Microbiota Research, Juntendo University School of Medicine Graduate School of Medicine, Bunkyo, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6612-6912","authenticated-orcid":false,"given":"Shigetaka","family":"Shimodaira","sequence":"additional","affiliation":[{"name":"Department of Regenerative Medicine, Kanazawa Medical University, Kahoku, Ishikawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruo","family":"Sugiyama","sequence":"additional","affiliation":[{"name":"Department of Cancer Immunology, The University of Osaka Graduate School of Medicine, Suita, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,7,31]]},"reference":[{"key":"2025100311104125000_13.7.e011426.1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.13027"},{"key":"2025100311104125000_13.7.e011426.2","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-021-08911-4","article-title":"Prognostic value of immune factors in the tumor microenvironment of patients with pancreatic ductal adenocarcinoma","volume":"21","author":"Kiryu","year":"2021","journal-title":"BMC Cancer"},{"key":"2025100311104125000_13.7.e011426.3","first-page":"1309","article-title":"Wilms\u2019 tumor 1 (WT1)-targeted cancer vaccines to extend survival for patients with pancreatic cancer","volume":"8","author":"Koido","year":"2016","journal-title":"Immunotherapy (Los Angel)"},{"key":"2025100311104125000_13.7.e011426.4","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-0314"},{"key":"2025100311104125000_13.7.e011426.5","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-17-0386"},{"key":"2025100311104125000_13.7.e011426.6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18103\/mra.v10i4.2762","article-title":"WT1 cancer vaccine for the treatment and prevention","volume":"10","author":"Sugiyama","year":"2022","journal-title":"MRAJ"},{"key":"2025100311104125000_13.7.e011426.7","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-0737"},{"key":"2025100311104125000_13.7.e011426.8","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009765","article-title":"Dendritic cells pulsed with multifunctional Wilms\u2019 tumor 1 (WT1) peptides combined with multiagent chemotherapy modulate the tumor microenvironment and enable conversion surgery in pancreatic cancer","volume":"12","author":"Koido","year":"2024","journal-title":"J Immunother Cancer"},{"key":"2025100311104125000_13.7.e011426.9","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics12040305","article-title":"Dendritic Cells Pre-Pulsed with Wilms\u2019 Tumor 1 in Optimized Culture for Cancer Vaccination","volume":"12","author":"Koya","year":"2020","journal-title":"Pharmaceutics"},{"key":"2025100311104125000_13.7.e011426.10","doi-asserted-by":"crossref","DOI":"10.3892\/ol.2022.13184","article-title":"WT1 epitope-specific IgG and IgM antibodies for immune-monitoring in patients with advanced sarcoma treated with a WT1 peptide cancer vaccine","volume":"23","author":"Alzaaqi","year":"2022","journal-title":"Oncol Lett"},{"key":"2025100311104125000_13.7.e011426.11","first-page":"2682","article-title":"Prognostic significance of Wilms\u2019 tumor 1 expression in patients with pancreatic ductal adenocarcinoma","volume":"16","author":"Kanai","year":"2018","journal-title":"Oncol Lett"},{"key":"2025100311104125000_13.7.e011426.12","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/00006676-199907000-00004","article-title":"p53 overexpression in lymph node metastases predicts clinical outcome in ductal pancreatic cancer","volume":"19","author":"Campani","year":"1999","journal-title":"Pancreas"},{"key":"2025100311104125000_13.7.e011426.13","first-page":"1125","article-title":"Predictive survival markers in patients with surgically resected non-small cell lung carcinoma","volume":"6","author":"Moldvay","year":"2000","journal-title":"Clin Cancer Res"},{"key":"2025100311104125000_13.7.e011426.14","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2015.145"},{"key":"2025100311104125000_13.7.e011426.15","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1080\/07357907.2019.1661427","article-title":"Clinical Significance of Tumor-Infiltrating T Cells and Programed Death Ligand-1 in Patients with Pancreatic Cancer","volume":"37","author":"Yoshida","year":"2019","journal-title":"Cancer Invest"},{"key":"2025100311104125000_13.7.e011426.16","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20201605","article-title":"Tissue-resident memory T cells in tumor immunity and immunotherapy","volume":"218","author":"Ok\u0142a","year":"2021","journal-title":"J Exp Med"},{"key":"2025100311104125000_13.7.e011426.17","doi-asserted-by":"crossref","first-page":"610","DOI":"10.3109\/00365521.2015.1121515","article-title":"Comprehensive assessment of the prognosis of pancreatic cancer: peripheral blood neutrophil-lymphocyte ratio and immunohistochemical analyses of the tumour site","volume":"51","author":"Takakura","year":"2016","journal-title":"Scand J Gastroenterol"},{"key":"2025100311104125000_13.7.e011426.18","doi-asserted-by":"publisher","DOI":"10.1002\/1878-0261.12727"},{"key":"2025100311104125000_13.7.e011426.19","doi-asserted-by":"publisher","DOI":"10.1111\/cas.14697"},{"key":"2025100311104125000_13.7.e011426.20","doi-asserted-by":"crossref","first-page":"5586","DOI":"10.4049\/jimmunol.153.12.5586","article-title":"The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes","volume":"153","author":"Sette","year":"1994","journal-title":"J Immunol"},{"key":"2025100311104125000_13.7.e011426.21","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.16679"},{"key":"2025100311104125000_13.7.e011426.22","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.ejca.2017.06.016","article-title":"Cytotoxic tumour-infiltrating T lymphocytes influence outcome in resected pancreatic ductal adenocarcinoma","volume":"83","author":"Lohneis","year":"2017","journal-title":"Eur J Cancer"},{"key":"2025100311104125000_13.7.e011426.23","doi-asserted-by":"publisher","DOI":"10.1172\/JCI32103"},{"key":"2025100311104125000_13.7.e011426.24","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.30182"},{"key":"2025100311104125000_13.7.e011426.25","doi-asserted-by":"crossref","DOI":"10.4161\/21624011.2014.958950","article-title":"Chemoimmunotherapy targeting Wilms\u2019 tumor 1 (WT1)-specific cytotoxic T lymphocyte and helper T cell responses for patients with pancreatic cancer","volume":"3","author":"Koido","year":"2014","journal-title":"Oncoimmunology"},{"key":"2025100311104125000_13.7.e011426.26","doi-asserted-by":"crossref","DOI":"10.1007\/s00262-024-03862-8","article-title":"Spontaneous high clonal expansion of Wilms\u2019 tumor gene 1-specific cytotoxic T-lymphocytes in patients with Wilms\u2019 tumor gene 1-expressing solid tumor","volume":"74","author":"Morimoto","year":"2024","journal-title":"Cancer Immunol Immunother"},{"key":"2025100311104125000_13.7.e011426.27","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2021.1954800","article-title":"In vitro OP9-DL1 co-culture and subsequent maturation in the presence of IL-21 generates tumor antigen-specific T cells with a favorable less-differentiated phenotype and enhanced functionality","volume":"10","author":"Bonte","year":"2021","journal-title":"Oncoimmunology"},{"key":"2025100311104125000_13.7.e011426.28","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-1708"},{"key":"2025100311104125000_13.7.e011426.29","doi-asserted-by":"crossref","first-page":"3323","DOI":"10.1007\/s00262-021-03003-5","article-title":"Identification of mouse helper epitopes for WT1-specific CD4+ T cells","volume":"70","author":"Nakajima","year":"2021","journal-title":"Cancer Immunol Immunother"},{"key":"2025100311104125000_13.7.e011426.30","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-10-2693"},{"key":"2025100311104125000_13.7.e011426.31","first-page":"731","article-title":"Epitope spreading contributes to effective immunotherapy in metastatic melanoma patients","volume":"3","author":"Hardwick","year":"2011","journal-title":"Immunotherapy (Los Angel)"},{"key":"2025100311104125000_13.7.e011426.32","doi-asserted-by":"publisher","DOI":"10.1038\/cdd.2013.67"},{"key":"2025100311104125000_13.7.e011426.33","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.3349"},{"key":"2025100311104125000_13.7.e011426.34","doi-asserted-by":"crossref","first-page":"12177","DOI":"10.3390\/ijms232012177","article-title":"The Detection of Immunity against WT1 and SMAD4P130L of EpCAM+ Cancer Cells in Malignant Pleural Effusion","volume":"23","author":"Koya","year":"2022","journal-title":"IJMS"},{"key":"2025100311104125000_13.7.e011426.35","doi-asserted-by":"publisher","DOI":"10.1038\/ni889"},{"key":"2025100311104125000_13.7.e011426.36","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.01613","article-title":"Circulating T Cell Subpopulations Correlate With Immune Responses at the Tumor Site and Clinical Response to PD1 Inhibition in Non-Small Cell Lung Cancer","volume":"9","author":"Manjarrez-Ordu\u00f1o","year":"2018","journal-title":"Front Immunol"},{"key":"2025100311104125000_13.7.e011426.37","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1158\/1078-0432.CCR-23-0445","article-title":"Tumor-Infiltrating CD103+ Tissue-Resident Memory T Cells and CD103\u2212CD8+ T Cells in HNSCC Are Linked to Outcome in Primary but not Metastatic Disease","volume":"30","author":"von Witzleben","year":"2024","journal-title":"Clin Cancer Res"},{"key":"2025100311104125000_13.7.e011426.38","doi-asserted-by":"crossref","first-page":"36029","DOI":"10.18632\/oncotarget.26338","article-title":"Extremely strong infiltration of WT1-specific CTLs into mouse tumor by the combination vaccine with WT1-specific CTL and helper peptides","volume":"9","author":"Nakata","year":"2018","journal-title":"Oncotarget"},{"key":"2025100311104125000_13.7.e011426.39","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-14-0027"},{"key":"2025100311104125000_13.7.e011426.40","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-2974"},{"key":"2025100311104125000_13.7.e011426.41","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.9.3272"},{"key":"2025100311104125000_13.7.e011426.42","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1007\/s00262-022-03202-8","article-title":"First-in-human study of WT1 recombinant protein vaccination in elderly patients with AML in remission: a single-center experience","volume":"71","author":"Kreutmair","year":"2022","journal-title":"Cancer Immunol Immunother"},{"key":"2025100311104125000_13.7.e011426.43","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-17-1298"},{"key":"2025100311104125000_13.7.e011426.44","doi-asserted-by":"crossref","DOI":"10.3390\/cells13010003","article-title":"A Comprehensive Review of the Potential Role of Liquid Biopsy as a Diagnostic, Prognostic, and Predictive Biomarker in Pancreatic Ductal Adenocarcinoma","volume":"13","author":"Stosic","year":"2023","journal-title":"Cells"},{"key":"2025100311104125000_13.7.e011426.45","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-1215"},{"key":"2025100311104125000_13.7.e011426.46","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-06-0012"},{"key":"2025100311104125000_13.7.e011426.47","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1002\/bjs.10187","article-title":"Infiltrating immune cells and gene mutations in pancreatic ductal adenocarcinoma","volume":"103","author":"Wang","year":"2016","journal-title":"Br J Surg"},{"key":"2025100311104125000_13.7.e011426.48","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1089\/gtmb.2020.0078","article-title":"Clinical Effect of Driver Mutations of KRAS, CDKN2A\/P16, TP53, and SMAD4 in Pancreatic Cancer: A Meta-Analysis","volume":"24","author":"Gu","year":"2020","journal-title":"Genet Test Mol Biomarke"},{"key":"2025100311104125000_13.7.e011426.49","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.33038"},{"key":"2025100311104125000_13.7.e011426.50","doi-asserted-by":"crossref","DOI":"10.1186\/s12967-024-04989-z","article-title":"High somatic mutations in circulating tumor DNA predict response of metastatic pancreatic ductal adenocarcinoma to first-line nab-paclitaxel plus S-1: prospective study","volume":"22","author":"Huang","year":"2024","journal-title":"J Transl Med"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2024-011426","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T18:10:50Z","timestamp":1759515050000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2024-011426"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":50,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,7,31]]},"published-print":{"date-parts":[[2025,7]]}},"alternative-id":["10.1136\/jitc-2024-011426"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2024-011426","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7]]}}}